The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (TA). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.

The present invention provides insertable medical devices having elastic surfaces associated with bioactive agent-containing microparticulates and a coating material. Upon expansion of the elastic surfaces the microparticulates can be released to a subject.

A stromal material for encapsulating cells, a preparation method therefor, and an application thereof. The material is prepared from the cartilage of mammals such as pigs, cows, sheep, horses, and deer by means of cutting, low-temperature micronization grinding, enzymolysis treatment, cell component removal, virus inactivation, freeze-drying, and irradiation sterilization treatment. The main components of the material are type II collagen, chondroitin sulfate, and hyaluronic acid. The material can be used in 3D bioprinting; encapsulating, or protecting, or encapsulating and protecting cells; for tissue regeneration and repair; or, for filling and inducing autologous adipose formation in the field of medical aesthetics.

Implants for anti-VEGF therapy provide both stability and controlled release of bevacizumab and other structurally sensitive polypeptides while maintaining protein/peptide stability in the micronized powder; achieving near zero order and complete release (>80%). Cylindrical implants suitable for intravitreal injection.

The disclosure relates to coatings that contain silver, either in the form of metallic silver, silver oxides, salts of silver, or combinations of these. The silver is present in a microparticulate or nanoparticulate form, which exerts antimicrobial activity when bacteria (e.g., in a body fluid) contact the coated surface. The coatings are applied through accumulation of silver-containing particles on the surface, such as by sputtering or electron beam vapor deposition. As a result, their thickness, particle size, and density can be controlled. Furthermore, the surface can also be coated with other substances, such as diamond-like carbon or alumina, either as a discrete layer or intermixed with the silver-containing particles.

A moist heat therapy compress for therapeutic treatment of a treated body part. The moist heat therapy compress includes a fluid-permeable shell, a flexible backing fastened to the shell to define an enclosure, and hydrophilic zeolite fill granules loosely contained within the enclosure. The moist heat therapy compress is exposed to a source of moisture to cause absorption of water into the hydrophilic zeolite, and the moisture is delivered from the hydrophilic zeolite through the fluid permeable shell to the treated body portion.

Particles of an organic acid salt of an amino acid amide or ester local anesthetic are employed as agents for the improved alleviation of pain. Particularly, the particles find use with surgically created wounds, where the particles may be administered directly into the bed of the wound or topically for transdermal transport.

Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

The invention relates to bioactive surface coatings deposited on selected substrates. Surface nanostructured film coatings deposited on most metal or nonmetal substrates to provide surfaces can be engineered to promote enhanced tissue/cell adhesion. Attached cells, including osteoblasts, fibroblasts and endothelial cells, retain viability and will readily differentiate and proliferate under appropriate conditions. Fibroblasts and endothelial cells exhibit good attachment and growth on most coated substrates, except on nano surfaced structured silicone.

The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (TA). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site.